Our website use cookies to improve and personalize your experience and to display advertisements(if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click on the button to check our Privacy Policy.
AI-driven mapping reveals 1,108 potential drug targets on the human surfaceome supported by published studies

AI-driven mapping reveals 1,108 potential drug targets on the human surfaceome supported by published studies

Contents
  1. Databases that disagree
  2. How the tool works
  3. An example: the KLK2 protein
  4. An open resource
  5. References

More than 65% of approved medicines work by binding to proteins on the surface of human cells, yet the major biological databases disagree on which proteins are actually there. The Deliverome Project, an open research initiative, used artificial intelligence to review the published evidence and build a map of the human surfaceome, the full set of cell surface proteins.

The map flags 1,108 candidate proteins that are missing from all five major reference databases but are supported by published studies. The findings were posted in October 2026 as a preprint on bioRxiv, so they have not yet been peer reviewed, and the proteins are candidates rather than confirmed targets.

Databases that disagree

The team compared five databases: UniProt, GO CC, the Human Protein Atlas, the Cell Surface Protein Atlas and SURFY. Together they list 5,546 surface proteins, but all five agree on only 188, according to the Hertz Foundation.

How the tool works

Co-founders Becca Carlson and Bobby Hollingsworth built an AI agent using the Claude Sonnet 4.6 model. The agent reviews the scientific literature to determine whether a protein sits on the cell surface.

On SurfaceBench, a hand-labeled collection consisting of 147 proteins, the agent achieved a 95.7% classification accuracy, whereas UniProt, which stood out as the top-performing database, reached roughly 90%.

An example: the KLK2 protein

All five databases classify the protein KLK2 as absent from the cell surface. However, research has found a membrane-anchored form enriched in prostate cancer, and an experimental therapy targeting it is in Phase 3 trials. Deliverome classifies KLK2 as able to appear on the surface under certain conditions.

An open resource

The map is free to explore in Open View, an interactive tool that shows each protein alongside its supporting research. The project also offers a public API and open-source code.

“My hope is that this will help people develop drugs that are more diverse and serve more patients and more indications,” said Carlson, a 2017 Hertz Fellow and the project’s co-CEO.

Deliverome launched on May 27, 2026, with $5 million in seed funding from the Astera Institute. It is set up as a Focused Research Organization, a model designed to deliver public research tools within about five years. Researchers from Coral Biosciences also co-authored the preprint.

References

By Miles Spencer

You May Also Like